Avidity Biosciences
Latest round
- Series C
Last raised
- Nov 2019
Total raised
- $126M
Investors
- 19
About Avidity Biosciences
Founded in 2013, Avidity Biosciences is dedicated to the development of RNA therapeutics. Sarah Boyce serves as the CEO. Avidity Biosciences specializes in creating a new class of targeted RNA therapeutics through its AOC™ platform, which combines monoclonal antibodies with oligonucleotides. The company aims to treat muscle diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Products are developed for North American markets, with potential expansion into Europe and Asia. The revenue model is based on partnerships and collaborations with pharmaceutical companies, involving milestone payments and royalties from the commercialization of its AOC™ platform and therapeutic candidates. In October 2025, Novartis International AG, agreed to fully acquire Avidity Biosciences, Inc from F-Prime Capital, TPG Biotech,Tavistock Group,Moore Venture Partners for USD 12 billion.
Who invested in Avidity Biosciences
19 investors across 4 rounds
See all investors in Avidity Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Avidity Biosciences
Who invested in Avidity Biosciences?
Avidity Biosciences has 19 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Avidity Biosciences last raise money?
Avidity Biosciences's most recent round on record is a Series C, in Nov 2019.
What does Avidity Biosciences do?
Founded in 2013, Avidity Biosciences is dedicated to the development of RNA therapeutics.
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in US.
Which VCs invest in companies like Avidity Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Avidity Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Avidity Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.